Reviews in Urology | |
Bacillus Calmette-Guérin Failures and Beyond: Contemporary Management of Non-Muscle-Invasive Bladder Cancer | |
Thomas E Keane1  Michael A O’Donnell1  Michael S Cookson1  Richard E Greenberg1  H. Barton Grossman1  | |
[1] *Department of Urology, The University of Texas M. D. Anderson Cancer Center, Houston, TX | |
关键词: Bladder cancer; Bacillus Calmette-Guérin; Cystectomy; Gemcitabine; Valrubicin; | |
DOI : | |
学科分类:基础医学 | |
来源: MedReviews, LLC | |
【 摘 要 】
In the United States, bacillus Calmette-Guérin (BCG) is the treatment most used for superficial bladder cancer. Patients with carcinoma in situ (CIS) treated with intravesical BCG plus interferon have a 60% to 70% chance of a complete and durable response if they were never treated with BCG or if they failed only 1 prior induction or relapsed more than a year from induction. Intravesical gemcitabine is safe, but its usefulness for BCG-refractory patients is unclear. Valrubicin, approved for intravesical treatment of BCG-refractory CIS of the bladder, has efficacy and acceptable toxicity. Cystectomy should be considered in high-risk, non-muscle-invasive cancer, particularly if intravesical therapy failed.
【 授权许可】
Unknown
【 预 览 】
Files | Size | Format | View |
---|---|---|---|
RO201912040560296ZK.pdf | 417KB | download |